{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:52:48Z","timestamp":1793649168583,"version":"4.5.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82103983"],"award-info":[{"award-number":["82103983"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2020A1515110430"],"award-info":[{"award-number":["2020A1515110430"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.ejmech.2023.115915","type":"journal-article","created":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T15:23:46Z","timestamp":1699025026000},"page":"115915","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Discovery of benzamide-based PI3K\/HDAC dual inhibitors with marked pro-apoptosis activity in lymphoma cells"],"prefix":"10.1016","volume":"262","author":[{"given":"Jingjing","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baogeng","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohan","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanze","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3684-2106","authenticated-orcid":false,"given":"Xiaoyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2023.115915_bib1a","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nchembio.118","article-title":"Network pharmacology: the next paradigm in drug discovery","volume":"4","author":"Hopkins","year":"2008","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2023.115915_bib1b","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1586\/ecp.12.74","article-title":"Polypharmacology: drug discovery for the future","volume":"6","author":"Reddy","year":"2013","journal-title":"Expet Rev. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115915_bib2","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/cmdc.201600161","article-title":"Multitarget drug discovery and polypharmacology","volume":"11","author":"Bolognesi","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2023.115915_bib3","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ejmech.2017.11.049","article-title":"Exploiting polypharmacology for improving therapeutic outcome of kinase inhibitors (KIs): an update of recent medicinal chemistry efforts","volume":"143","author":"Ma","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115915_bib4","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1021\/acs.jmedchem.8b00760","article-title":"Polypharmacology by design: a medicinal chemist's perspective on multitargeting compounds","volume":"62","author":"Proschak","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115915_bib5","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.chembiol.2019.06.003","article-title":"Divergent polypharmacology-driven cellular activity of structurally similar multi-kinase inhibitors through cumulative effects on individual targets","volume":"26","author":"Sumi","year":"2019","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2023.115915_bib6","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/nrd1902","article-title":"Exploiting the PI3K\/AKT pathway for cancer drug discovery","volume":"4","author":"Hennessy","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2023.115915_bib7","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.3390\/cancers2031576","article-title":"The emerging role of the phosphatidylinositol 3-kinase\/Akt\/mammalian target of rapamycin signaling network in cancer stem cell biology","volume":"2","author":"Martelli","year":"2010","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2023.115915_bib8","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1200\/JCO.2009.25.3641","article-title":"The PI3K pathway as drug target in human cancer","volume":"28","author":"Courtney","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2023.115915_bib9","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/nrg1879","article-title":"The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism","volume":"7","author":"Engelman","year":"2006","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ejmech.2023.115915_bib10","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1126\/science.1150799","article-title":"The structure of a human p110\u03b1\/p85\u03b1 complex elucidates the effects of oncogenic PI3K\u03b1 mutations","volume":"318","author":"Huang","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2023.115915_bib11","doi-asserted-by":"crossref","first-page":"5486","DOI":"10.1038\/onc.2008.244","article-title":"Class I PI3K in oncogenic cellular transformation","volume":"27","author":"Zhao","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2023.115915_bib12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nrc3860","article-title":"PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting","volume":"15","author":"Thorpe","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2023.115915_bib13","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nrc2664","article-title":"Targeting PI3K signalling in cancer: opportunities, challenges and limitations","volume":"9","author":"Engelman","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2023.115915_bib14a","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1007\/s40265-014-0285-6","article-title":"Idelalisib: first global approval","volume":"74","author":"Markham","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2023.115915_bib14b","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1007\/s40265-017-0838-6","article-title":"Copanlisib: first global approval","volume":"77","author":"Markham","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2023.115915_bib14c","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1007\/s40265-018-1013-4","article-title":"Duvelisib: first global approval","volume":"78","author":"Blair","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2023.115915_bib14d","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s40265-019-01161-6","article-title":"Alpelisib: first global approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2023.115915_bib14e","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s40265-021-01504-2","article-title":"Umbralisib: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2023.115915_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114039","article-title":"Molecular design of dual inhibitors of PI3K and potential molecular target of cancer for its treatment: a review","volume":"228","author":"Wang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115915_bib16","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.3390\/ijms18071414","article-title":"Histone deacetylase inhibitors as anticancer drugs","volume":"18","author":"Eckschlager","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2023.115915_bib17","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1021\/acs.jmedchem.8b00189","article-title":"Kinase and histone deacetylase hybrid inhibitors for cancer therapy","volume":"62","author":"Luan","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115915_bib18","doi-asserted-by":"crossref","first-page":"8198","DOI":"10.3390\/ijms21218198","article-title":"Histone deacetylase inhibitors as multitarget-directed epi-drugs in blocking PI3K oncogenic signaling: a polypharmacology approach","volume":"21","author":"Ranganna","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2023.115915_bib19","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/cmdc.202000643","article-title":"Multitarget inhibition of histone deacetylase (HDAC) and phosphatidylinositol\u20103\u2010kinase (PI3K): current and future prospects","volume":"16","author":"Rodrigues","year":"2021","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2023.115915_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114039","article-title":"Molecular design of dual inhibitors of PI3K and potential molecular target of cancer for its treatment: a review","volume":"228","author":"Wang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115915_bib21","doi-asserted-by":"crossref","first-page":"4849","DOI":"10.1158\/1078-0432.CCR-14-0034","article-title":"PI3K\/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM-and MCL-1\u2013dependent mechanisms in vitro and in vivo","volume":"20","author":"Rahmani","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2023.115915_bib22","doi-asserted-by":"crossref","first-page":"11937","DOI":"10.18632\/oncotarget.14442","article-title":"PI3K\/mTOR dual inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A synergistically exert anti-tumor activity in breast cancer","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2023.115915_bib23","first-page":"93","article-title":"Enhanced efficacy of histone deacetylase inhibitor panobinostat combined with dual PI3K\/mTOR inhibitor BEZ235 against glioblastoma","volume":"81","author":"Meng","year":"2019","journal-title":"Nagoya J. Med. Sci."},{"key":"10.1016\/j.ejmech.2023.115915_bib24","doi-asserted-by":"crossref","first-page":"60169","DOI":"10.18632\/oncotarget.11109","article-title":"Superior efficacy of co-treatment with the dual PI3K\/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A against NSCLC","volume":"7","author":"Piao","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2023.115915_bib25","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1158\/1078-0432.CCR-12-0055","article-title":"Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling","volume":"15","author":"Qian","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2023.115915_bib26","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S1470-2045(15)00584-7","article-title":"Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2023.115915_bib27","doi-asserted-by":"crossref","first-page":"5044","DOI":"10.1158\/1078-0432.CCR-17-1043","article-title":"Dual inhibition of HDAC and tyrosine kinase signaling pathways with CUDC-907 inhibits thyroid cancer growth and metastases","volume":"23","author":"Kotian","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2023.115915_bib28","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.3324\/haematol.2018.201343","article-title":"Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia","volume":"104","author":"Li","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.ejmech.2023.115915_bib29","doi-asserted-by":"crossref","first-page":"7239","DOI":"10.1111\/jcmm.15281","article-title":"CUDC\u2010907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: antitumour activity and molecular mechanism of action","volume":"24","author":"Hu","year":"2020","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.ejmech.2023.115915_bib30","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/bjh.17730","article-title":"Fimepinostat (CUDC\u2010907) in patients with relapsed\/refractory diffuse large B cell and high\u2010grade B\u2010cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses","volume":"195","author":"Landsburg","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejmech.2023.115915_bib31","doi-asserted-by":"crossref","first-page":"5488","DOI":"10.1021\/acs.jmedchem.6b00579","article-title":"Development of purine-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities","volume":"59","author":"Chen","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115915_bib32","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1021\/acs.jmedchem.7b01465","article-title":"Design, synthesis, and preclinical evaluation of fused pyrimidine-based hydroxamates for the treatment of hepatocellular carcinoma","volume":"61","author":"Chen","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115915_bib33","doi-asserted-by":"crossref","first-page":"52180","DOI":"10.1039\/C7RA08835C","article-title":"Design, synthesis and biological evaluation of 2,3-dihydroimidazo [1,2-c] quinazoline derivatives as novel phosphatidylinositol 3-kinase and histone deacetylase dual inhibitors","volume":"7","author":"Wu","year":"2017","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2023.115915_bib34","doi-asserted-by":"crossref","first-page":"6992","DOI":"10.1021\/acs.jmedchem.9b00390","article-title":"Design, synthesis, and biological evaluation of 4-methyl quinazoline derivatives as anticancer agents simultaneously targeting phosphoinositide 3-kinases and histone deacetylases","volume":"62","author":"Zhang","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115915_bib35","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/cmdc.201900716","article-title":"Design, synthesis, and pharmacological evaluation of first\u2010in\u2010class multitarget N\u2010acylhydrazone derivatives as selective HDAC6\/8 and PI3K\u03b1 inhibitors","volume":"15","author":"Rodrigues","year":"2020","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2023.115915_bib36","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1021\/acs.jmedchem.0c00193","article-title":"Design, synthesis, and biological evaluation of quinazolin-4-one-based hydroxamic acids as dual PI3K\/HDAC inhibitors","volume":"63","author":"Thakur","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115915_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115673","article-title":"A review of progress in o-aminobenzamide-based HDAC inhibitors with dual targeting capabilities for cancer therapy","volume":"259","author":"Zhang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115915_bib40","doi-asserted-by":"crossref","first-page":"17598","DOI":"10.1074\/jbc.M117.804328","article-title":"Isoform-selective inhibitor of histone deacetylase 3 (HDAC3) limits pancreatic islet infiltration and protects female nonobese diabetic mice from diabetes","volume":"43","author":"Dirice","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.115915_bib41","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1016\/S1470-2045(13)70579-5","article-title":"Drug\u2013drug interactions with tyrosine-kinase inhibitors: a clinical perspective","volume":"15","author":"van Leeuwen","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2023.115915_bib42","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2174\/187231207780363642","article-title":"Disposition of vorinostat, a novel histone deacetylase inhibitor and anticancer agent, in preclinical species","volume":"1","author":"Sandhu","year":"2007","journal-title":"Drug Metabol. Lett."},{"key":"10.1016\/j.ejmech.2023.115915_bib43","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1200\/JCO.2005.02.188","article-title":"Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma","volume":"23","author":"Ryan","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2023.115915_bib44","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1021\/jm901830p","article-title":"Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase\/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor","volume":"53","author":"Venkatesan","year":"2010","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423008826?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423008826?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:05:01Z","timestamp":1777529101000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523423008826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":47,"alternative-id":["S0223523423008826"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115915","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of benzamide-based PI3K\/HDAC dual inhibitors with marked pro-apoptosis activity in lymphoma cells","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115915","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115915"}}